Showing 2630 results
- https://www.novartis.com/news/media-releases/novartis-et-medicines-malaria-venture-lancent-une-etude-clinique-en-afrique-pour-kaf156-un-candidat-medicament-novateur-contre-le-paludisme-multiresistantCe candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la…
- https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-launch-patient-trial-africa-kaf156-novel-compound-against-multidrug-resistant-malariaCompound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first…
- https://www.novartis.com/news/media-releases/novartis-und-medicines-malaria-venture-starten-afrika-eine-patientenstudie-mit-kaf156-einem-neuartigen-wirkstoff-gegen-multiresistente-malariaDer Wirkstoff führt zu rascher Parasitenfreiheit auch bei resistenten Erregerstämmen, blockiert die Übertragung der Erreger und könnte damit eine Wende im Kampf gegen Malaria herbeiführen.…
- https://www.novartis.com/news/media-releases/novartis-presents-results-from-first-global-registration-trial-ctl019-pediatric-and-young-adult-patients-rr-b-all82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T…
- https://www.novartis.com/news/media-releases/novartis-seg101-crizanlizumab-formerly-selg1-significantly-reduces-frequency-sickle-cell-pain-crises-phase-ii-studySEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-…
- https://www.novartis.com/news/media-releases/novartis-access-communique-son-bilan-un-et-annonce-la-signature-dun-protocole-daccord-avec-le-rwandaLe Rwanda devient le troisième pays à lancer Novartis Access, un programme de distribution de médicaments pour traiter les maladies chroniques dans les pays à faible revenu. Les premières livraisons…
- https://www.novartis.com/news/media-releases/novartis-access-shares-one-year-learnings-and-announces-memorandum-understanding-rwandaRwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than…
- https://www.novartis.com/news/media-releases/novartis-access-informiert-uber-erfahrungen-im-ersten-jahr-und-gibt-memorandum-understanding-mit-ruanda-bekanntRuanda ist das dritte Land, welches das Portfolio von Novartis Access gegen chronische Krankheiten einführen wird. Die ersten Medikamentenlieferungen sind für Anfang 2017 geplant. Seit September…
- https://www.novartis.com/news/media-releases/novartis-acquires-selexys-pharmaceuticals-corporation-and-selg1-antibody-reduction-pain-crises-sickle-cell-disease-scdDeal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options Results of SUSTAIN will be…
- https://www.novartis.com/news/media-releases/novartis-commends-publication-major-report-which-recommends-broad-use-dual-bronchodilators-treat-copd2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro® Breezhaler®, in the treatment of the majority of symptomatic COPD patients Bronchodilation regarded…
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- 263
- › Next page